The percentages of subjects with elevated tumor marker levels that were maintained in the next test were 36, 37, 37, and 28% for CYFRA 21 − 1 and 60, 75, 83, and 71% for CEA over four years (Table II). This evidence concerns the gene CEACAM5 and neoplasm.